Disclaimer: This article is for informational purposes only and does not replace the full Prescribing Information or professional medical advice
Full marks here
The phase 2b ENLIVEN trial, a multicenter, randomized, double-blind, placebo-controlled study, included 222 patients with biopsy-confirmed NASH and F2-F3 fibrosis, assigned to receive pegozafermin at doses of 15 mg weekly, 30 mg weekly, 44 mg every 2 weeks, or placebo for 24 weeks
Very satisfied with overall experience
But the compounded drugs these telemedicine companies have been selling can come with health risksand research shows that some telehealth sites might be misleading customers
Body Composition Changes During Weight Reduction With Tirzepatide in the SURMOUNT-1 Study of Adults With Obesity or Overweight